+

WO2003082359A1 - Traitement de tissu - Google Patents

Traitement de tissu Download PDF

Info

Publication number
WO2003082359A1
WO2003082359A1 PCT/US2003/009467 US0309467W WO03082359A1 WO 2003082359 A1 WO2003082359 A1 WO 2003082359A1 US 0309467 W US0309467 W US 0309467W WO 03082359 A1 WO03082359 A1 WO 03082359A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
tissue
region
selecting
composition
Prior art date
Application number
PCT/US2003/009467
Other languages
English (en)
Inventor
George Bourne
Marcia Buisier
Thomas V. Ii Casey
Steve Keenan
Janel Lanphere
Jianmin Li
Erin Mckenna
Zarouhi Minasian
Doreen Rao
Original Assignee
Boston Scientific Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/109,966 external-priority patent/US7094369B2/en
Priority claimed from US10/231,664 external-priority patent/US7131997B2/en
Application filed by Boston Scientific Limited filed Critical Boston Scientific Limited
Priority to CA002480630A priority Critical patent/CA2480630A1/fr
Priority to EP03719492A priority patent/EP1490119A1/fr
Priority to AU2003223372A priority patent/AU2003223372A1/en
Priority to JP2003579891A priority patent/JP4364649B2/ja
Publication of WO2003082359A1 publication Critical patent/WO2003082359A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0004—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse
    • A61F2/0031—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra
    • A61F2/0036—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse for constricting the lumen; Support slings for the urethra implantable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
    • C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
    • C08J2329/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids

Definitions

  • This invention relates to the treatment of tissue, such as the introduction of particles into body tissue for repair and/or augmentation.
  • the body includes various passageways through which bodily matter or fluids, such as urine, can flow.
  • the flow of material through the passageways is in part affected by tissue surrounding the passageways.
  • tissue can constrict and cause a passageway to narrow or to close, thereby restricting flow of material through the passageway.
  • the tissue can no longer affect a passageway.
  • urine normally flows down in one direction from the kidneys, through tubes called ureters, and to the bladder, in vesicoureteral reflux (VUR)
  • VUR vesicoureteral reflux
  • urine can flow abnormally from the bladder back into the ureters.
  • gastroesophageal reflux disease sometimes called "reflux”
  • acid from the stomach can flow back into the swallowing tube, or esophagus.
  • Other disorders include, for example, urinary incontinence, i.e., loss of urinary control, and fecal incontinence.
  • One method of treating such disorders includes placing, e.g., injecting, a bulking material in the tissue adjacent to the passageway.
  • the bulking material can narrow the passageway and, by providing bulk, allows the tissue to constrict the passageway more easily.
  • This invention relates to the treatment of tissue.
  • the invention features a method of treating tissue including placing substantially spherical polymer particles in the tissue.
  • the particles have an interior region having relatively large pores and a first region substantially surrounding the interior region having fewer relatively large pores than the interior region.
  • Embodiments may include one or more of the following features.
  • the particles are injected into the tissue.
  • the particles are injected percutaneously.
  • the particles are delivered through a catheter.
  • the method includes forming a cavity in the tissue, and placing the particles in the cavity.
  • the tissue is adjacent to a body passageway.
  • the passageway is defined by a ureter.
  • the tissue is adjacent to a body passageway, and the particles are placed in an amount effective to narrow the passageway.
  • the particles can be polyvinyl alcohol.
  • the polyvinyl alcohol can be 1,3 diol acetalized.
  • the particles can include a polysaccharide.
  • the polysaccharide can include alginate.
  • the particles can include a therapeutic agent.
  • the invention features a method of treating an individual.
  • the method includes placing a therapeutically effective amount of substantially spherical particles including polyvinyl alcohol in a tissue of the individual.
  • the particles have an interior region having relatively large pores and a first region substantially surrounding the interior region having fewer relatively large pores than the interior region.
  • Embodiments can include one or more of the following features.
  • the method further includes selecting the individual diagnosed with gastroesophageal reflux disease.
  • the tissue is adjacent to a gastrointestinal tract.
  • the method further includes selecting the individual diagnosed with vesicoureteral reflux.
  • the tissue is adjacent to a ureter.
  • the method can further include selecting an individual diagnosed with urinary incontinence, fecal incontinence, intrinsic sphincteric deficiency, and/or vocal cord paralysis.
  • the method can further include selecting an individual in need of a reconstructive or cosmetic procedure.
  • the particles can be placed percutaneously and/or through a catheter.
  • the invention features a method of delivering a therapeutically effective amount of substantially spherical polymer particles.
  • the particles include polyvinyl alcohol and include an interior region having relatively large pores and a surface region having fewer relatively large pores.
  • the particles can have a diameter of about 1200 micron or less, a surface with a predominant pore size of about 2 micron or less and pores interior to surface of about 10 micron or more, and/or a surface region from about 0.8r to r, the predominant pore size in the surface region being smaller than the predominant pore size in a region C to 0.3r.
  • Embodiments may also include one or more of the following.
  • the relatively large pores are about 20 or 30 micron or more.
  • the surface region is about r to 0.8r.
  • the surface region is about r to 2/3r.
  • the particles include a body region from about 2/3r to r/3 including intermediate size pores and the body region has more intermediate size pores than the surface region.
  • the center region is from about r/3 to C, the outer region including large size pores and the body region has fewer large size pores than the center region.
  • the intermediate size pores are about 2 to 18 microns.
  • the surface region is substantially free of pores greater than about 5 micron.
  • Embodiments may also include one of the following.
  • the predominant pore size progressively increases from surface to the center of the particle.
  • the predominant pore size on the particle surface is about 1 micron or less.
  • the particles have a surface region from about (2r)/3 to the surface wherein the predominant pore size is in the range of about 1 micron or less.
  • the predominant pore size is about 0.1 micron or less.
  • Interior of said surface region, the particles have a predominant pore size in the range of about 2 to 35 microns.
  • the particles include a center region from about r to r/3 in which the predominant pore size is about 20 to 35 micron.
  • the particles have a body region from r/3 to (2r)/3 in which the predominant pore size is about 2 to 18 micron.
  • the particles have a surface region from about (2r)/3 to the periphery and the predominant pore size in the surface region is about 10% or less than the predominant pore size in the interior to the surface region.
  • the particles include a surface region from about 0.8r to r wherein the predominant pore size is about 1 micron or less.
  • the particles include a region from about C to 0.8r includes pores having a diameter of 10 microns or more.
  • the region C to 0.8r has a predominant pore size of about 3.5 to 2 micron.
  • the particles have a density of about 1.1 to about 1.4 g/cm3.
  • the particles have a density of about 1.2 to 1.3 g/cm 3 .
  • the particles have a sphericity of about 90% or more.
  • the particles have an initial sphericity of about 97% or more.
  • the particles have a sphericity of about 0.90 after compression to about 50%.
  • the particles have a size uniformity of about +
  • Embodiments may also include one or more of the following.
  • the particles include about 1 % or less polysaccharide.
  • the polysaccharide is alginate.
  • the alginate has a guluronic acid content of about 60% or greater.
  • the particles are substantially insoluble in DMSO.
  • the particles are substantially free of animal-derived compounds.
  • the polyvinyl alcohol is composed of substantially unmodified polyvinyl alcohol prepolymer.
  • the polyvinyl alcohol is predominantly intrachain 1, 3-diols acetalized.
  • the composition includes saline and/or contrast agent. The particles and/or composition are sterilized.
  • Embodiments may also include one or more of the following.
  • the gelling compound is a polysaccharide.
  • the gelling compound is alginate.
  • the alginate has a guluronic acid content of about 60% or more.
  • the drops are contacted with a gelling agent.
  • the gelling agent is a divalent cation.
  • the cation is Ca+2.
  • the base polymer is PNA.
  • the PNA is reacted by acetalization.
  • the PNA has a molecular weight of about 75,000 g/mole or greater.
  • the viscosity of the base polymer and gelling compound is modified prior to forming said drops.
  • the viscosity is modified by heating.
  • the drops are formed by vibratory nebulization.
  • Embodiments may also include one or more of the following.
  • Administration is by percutaneous injection.
  • Administration is by a catheter.
  • the particles are introduced to the body through a lumen, and the lumen has a smaller diameter than the particles.
  • the particles can be tailored to a particular application by varying particle size, porosity gradient, compressibility, sphericity and density of the particles.
  • the uniform size of the spherical particles can, for example, fit through the aperture of a needle or a catheter for administration by injection to a target site without partially or completely plugging the lumen of the needle or the catheter. Size uniformity of + 15% of the spherical particles allows the particles to stack evenly.
  • Embodiments may have one or more of the following advantages.
  • the particles are relatively inert and biocompatible (e.g., they do not trigger an allergic or cytotoxic response).
  • the particles do not substantially migrate, which can cause adverse effects.
  • the particles are relatively non-bioresorbable. As a result, the particles retain their efficacy, and the need for repeated procedures is reduced, which can lower cost, trauma, and/or complications.
  • the particles can be used in a variety of applications.
  • FIGs. 1 A and IB illustrate a method of treating tissue.
  • Fig. 2 illustrates a method of treating tissue.
  • Fig. 3A is a light micrograph of a collection of hydrated particles
  • Fig. 3B is a scanning electron microscope (SEM) photograph of the particle surface
  • Figs. 3C-3E are cross-sections of the particles.
  • Fig. 4 A is a schematic of the manufacture of a composition
  • Fig. 4B is an enlarged schematic of region A in Fig. 4A.
  • Fig. 5 is a photograph of gel-stabilized drops.
  • Fig. 6 is a graph of particle size uniformity.
  • Figs. 7A-7F illustrate a method of treating tissue.
  • a method of treating tissue 20, here, located adjacent to a passageway 22, is shown.
  • Passageway 22 is defined by a wall 24, e.g., of a urethra or a ureter.
  • the method generally includes placing a composition 27 including highly water insoluble, high molecular weight polymer particles 25 into tissue 20.
  • Particles 25, e.g., acetalized polyvinyl alcohol, have a substantially uniform shape and a symmetric compressibility.
  • Particles 25 can increase bulk and localize compression, thereby reducing the size of passageway 22 and assisting tissue 20 in closing to reduce (e.g., minimize or eliminate) flow of matter, such as urine, through the passageway.
  • composition 27 can include other materials, such as a carrier, a contrasting agent, and/or a therapeutic agent.
  • the method includes injecting composition 27 into tissue 20.
  • a cytoscope 26 is introduced into passageway 22 by conventional cytoscopic techniques.
  • Cytoscope 26 includes an elongated sheath 28 that defines a channel 30.
  • cytoscope 26 includes a light emitting element 32 (such as an optic fiber) and a viewing element 34.
  • Cytoscope 26 is positioned at a location selected to view a target area 36 to be treated.
  • a needle 38 is inserted into tissue 20 to target area 36, but without penetrating wall 24.
  • Composition 27 including particles 25 is then injected from a syringe (not shown) to area 36.
  • the progress of the injection can be monitored, for example, by viewing changes, e.g., narrowing, in passageway 22 through cytoscope 26 or by fluoroscopic or spectroscopic techniques, e.g., in embodiments in which composition 27 includes a contrasting agent (described below).
  • composition 27 includes a contrasting agent (described below).
  • needle 38 is inserted through channel 30 of cytoscope 26 to deliver composition 27.
  • composition 27 can be used to treat urinary incontinence.
  • Composition 27 can be injected into the tissue of the urinary tract, wherein the selected site can be, for example, the mucosal tissue of the bladder neck, the urethra or urethral sphincter.
  • the resulting bulking or augmentation of the urethral tissue can reduce or restrict the size of the urethra or urinary passage and thus assist in overcoming incontinence.
  • Composition 27 can be injected into the tissue of the anal canal, wherein the selected site can be, for example, the mucosal tissue of the anal canal, such as near the internal or external anal sphincter muscle.
  • the resulting bulking or augmentation of the tissue can restrict the size of the sphincter or anal passage and thus assist in reducing fecal or anal incontinence.
  • Composition 27 can also be used to treat, e.g., repair, structurally defective and/or inadequately functioning muscles of the anal sphincter.
  • composition 27 can be used to treat vesicoureteral reflux.
  • compositions e.g., a keyhole deformity resulting from trauma or surgery, using one or more injections, until the deformity is repaired or the treated area is restored to its proper form.
  • a deformity e.g., a keyhole deformity resulting from trauma or surgery
  • Methods of placing biocompatible materials to treat the sphincter muscles are described in Freed, U.S. 5,490,984.
  • Composition 27 can be applied to gastroesophageal reflux disease (GERD) applications.
  • Composition 27 can be injected into the mucosal tissue of the upper gastrointestinal tract, wherein the selected site may be, for example, the mucosal tissue of the cardiac orifice of the stomach, which opens into the esophagus.
  • the resulting bulking or augmentation of the tissue can restrict the size of the passage and thus assist in reducing gastric fluids refluxing into the esophagus.
  • Methods and techniques are described, for example, in Shafik, "Intraesophageal Polytef Injection for the Treatment of Reflux Esophagitis", Surg. Endoscopy, 10:329-331 (1996), and references cited therein.
  • Composition 27 can also be used to treat other conditions, such as vocal cord paralysis, e.g., to restore glottic competence in cases of paralytic dysphonia.
  • vocal cord paralysis e.g., to restore glottic competence in cases of paralytic dysphonia.
  • Such general treatment methods are described in Hirano et al., "Transcutaneous Intrafold Injection for Unilateral Vocal Cord Paralysis: Functional Results", Ann. Otol. Rhinol. Laryngol., Vol. 99, pp. 598-604 (1990); Strasnick et al., “Transcutaneous Teflon® Injection for Unilateral Vocal Cord Paralysis: An Update", Laryngoscope, Vol. 101, pp. 785-787 (July 1991); and references cited therein.
  • composition 27 is used to treat soft tissue.
  • composition 27 can be used for reconstructive or cosmetic applications, e.g., surgery. Examples of applications include reconstruction of cleft lips; scars, e.g., depressed scars from chicken pox or acne scars; indentations resulting from liposuction; wrinkles, e.g., glabella frown wrinkles; and soft tissue augmentation of thin lips.
  • Composition 27 can be used as a graft material or a filler to fill and/or to smooth out soft tissue defects.
  • composition 27 can be injected percutaneously under a defect until the appearance of the defect, e.g., a wrinkle, is reduced.
  • the amount of composition 27 delivered can vary based on the nature, location and severity of the condition to be treated and the route of administration, the size of particles 25, and factors relating to the patient.
  • a physician treating the condition, disease or disorder can determine an effective amount of composition 27.
  • An effective amount of composition 27 refers to the amount sufficient to result in amelioration of symptoms or a prolongation of survival of the patient.
  • particles 25 can also be used for implantable prostheses, such as mammary or breast implants, penile implants, or testicular prostheses.
  • particles 25 can be encased in a shell made of compliant material, such as silicone elastomers, polyolefins, polyurethanes, ethylene-propylene diene monomers, or ethylene- propylene rubbers.
  • particles 25 can be used without a shell because they can remain at the delivery site and do not migrate. Prostheses are described, for example, in U.S. 5,941,909; U.S. 6,060,639; U.S. 5,063,914; and references cited therein.
  • composition 27 includes polymer particles 25.
  • composition 27 also includes a carrier, a contrasting agent, and/or a therapeutic agent.
  • the particles: Particles 25 are substantially formed of polymer such as a highly water insoluble, high molecular weight polymer.
  • a preferred polymer is high molecular weight polyvinyl alcohol (PVA) that has been acetalized.
  • PVA polyvinyl alcohol
  • the particles are substantially pure intrachain 1,3 acetalized PVA and substantially free of animal derived residue such as collagen.
  • the particles include a minor amount, e.g. less than about 0.2 weight %, of alginate or another polysaccharide or gelling material.
  • particles 111 have a substantially uniform spherical shape and size.
  • each particle has a well-defined outer spherical surface including relatively small, randomly located pores. The surface appears substantially smooth, with some larger surface morphology such as crevice-like features.
  • Figs. 3C-3E SEM images of cross-sections through particles, the body of the particle defines pores which provide compressibility and other properties. Pores near the center of the particle are relatively large and pores near the surface of the particle are relatively small.
  • variable pore size profile produces a symmetric compressibility and, it is believed, a compressibility profile such that the particles are relatively easily compressed from a maximum, at rest diameter to a smaller, compressed first diameter but compression to even smaller diameter requires substantially greater force.
  • a variable compressibility profile is believed to be due to the presence of a relative weak, collapsible inter-pore wall structure in the center region where the pores are large, and a stiffer inter-pore wall structure near the surface of the particle, where the pores are more numerous and relatively small.
  • the variable pore size profile also is believed to enhance elastic recovery after compression.
  • the pore structure also influences the density of the particles and the rate of carrier fluid or body fluid uptake.
  • the particles can be delivered through a needle having a lumen area that is smaller, e.g. 50% smaller or less, than the uncompressed cross-sectional area of the particles.
  • the compression force is provided indirectly by increasing the pressure applied to the carrier fluid by depressing the syringe plunger.
  • the particles are relatively easily compressed to diameters sufficient for delivery through the needle into the body.
  • the robust, rigid surface region resists abrasion when the particles contact hard surfaces such as syringe surfaces, and the needle lumen wall (e.g. stainless steel) during delivery.
  • the particles substantially recover to original diameter and shape, and form a dense mass.
  • the compression can be limited by the compression profile of the particles, and the number of particles needed at a particular target area can be reduced.
  • the particles have a diameter of about 1500 or 1200 microns or less, and about 10 microns or more, e.g. about 400 microns or more and the pores are about 50 or 35 to 0.01 micron.
  • the particles can be classified in size ranges of about 500-700 microns, about 700-900 microns, or about 900-1200 microns.
  • the particles typically have a mean diameter in approximately the middle of the range and variance of about 20% or less, e.g. 15% or 10% or less.
  • the particular size of the particles used can also be a function of their application.
  • relatively small particles can be used to provide a more natural feel and to reduce a granular texture. Small particles can also be delivered through small needles, which can reduce psychological trauma and discomfort to the patient.
  • the particles can be considered to include a center region, C, from the center of the particle to a radius of about r/3, a body region, B, from about r/3 to about 2 r/3 and a surface region, S, from 2r/3 to r.
  • the regions can be characterized by the relative size of the pores and the number of pores of given sizes.
  • the center region has a greater number of relatively large pores than the body region and the surface region.
  • the large pores are in the range of about 20 micron or more, e.g. 30 micron or more, or in the range of about 20 to 35 micron.
  • the body region has a greater number of intermediate size pores than the surface region.
  • the intermediate size pores are in the range of about 5 to 18 micron.
  • the regions may also have different densities, with the density of the surface region being greater than the density of the body region, and the density of the body region being greater than the density of the center region.
  • the size of the pores in each of the regions can also be characterized by a distribution.
  • the predominant pore size(s) in the center region being greater than the predominant pore size(s) in the body region and the predominant pore size(s) in the body region is greater than the predominant pore size(s) in the surface region.
  • in the predominant pore size in the center region is 20 micron or more, e.g. 30 microns or more, or in the range of about 20 to 35 microns.
  • the predominant pore size in the body region is about 18 micron or less, e.g. about 15 micron or less, or in the range of about 18 to 2 micron.
  • the pores in the surface region are preferably predominantly less than about 1 micron, e.g. about 0.1 to 0.01 micron.
  • the predominant pore size in the body region is about 50 to 70% of the pore size in the center region and the pore size in the surface region is about 10% or less, e.g. about 2% of the pore size in the body region.
  • the size of the pores on the outer surface of the particle is predominantly in the range of about 1 micron or less, e.g. about 0.1 or 0.01 micron.
  • the surface and or surface region is substantially free of pores having a diameter larger than about 10 micron or larger than about 1 micron.
  • the predominant pore size is in the region 0.8 or 0.9r to r is about 1 micron or less, e.g. 0.5 to 0.1 micron or less.
  • the region from the center of the particle to 0.8 or 0.9r has pores of about 10 micron or greater and/or has a predominant pore size of about 2 to 35 micron.
  • the predominant pore size in the region 0.8 or 0.9r to r is about 5% or less, e.g. 1% or 0.3 % or less than the predominant pore size in the region from the center to 0.9r.
  • the largest pores in the particles can have a size in the range of 1% or 5% or 10% or more of the particle diameter.
  • the size of the pores can be measured by viewing a cross-section as in Fig. 3C. For irregularly shaped pores, the maximum visible cross-section is used.
  • the predominant pore size(s) can be found by measuring the size of the visible pores and plotting the number of pores as a function of size. The predominant pore size(s) are the sizes that are about the maximum in the distribution.
  • the SEM was taken on wet particles including absorbed saline, which were frozen in liquid nitrogen and sectioned. (Fig. 3B was taken prior to sectioning.)
  • Figs. 3D and 3E the particle was freeze-dried prior to sectioning and SEM analysis.
  • a system for manufacturing particles includes a flow controller
  • the flow controller 300 delivers polymer solutions to a viscosity controller 305, which heats the solution to reduce viscosity prior to delivery to the drop generator 310.
  • the drop generator 310 forms and directs drops into a gelling vessel 320, where drops are stabilized by gel formation.
  • the gel-stabilized drops are transferred from the gelling vessel 320 to reactor vessel 330 where the polymer in the gel-stabilized drops is reacted forming precursor particles.
  • the precursor particles are transferred to a gel dissolution chamber 340, where the gel is dissolved.
  • the particles are then filtered in a filter 350 to remove debris, sterilized, and packaged.
  • a base polymer and a gelling precursor are dissolved in water and mixed.
  • the mixture is introduced to a high pressure pumping apparatus, such as a syringe pump (e.g., model PHD4400, Harvard Apparatus, Holliston, MA).
  • a high pressure pumping apparatus such as a syringe pump (e.g., model PHD4400, Harvard Apparatus, Holliston, MA).
  • base polymers include polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, poly vinyl sulfonate, carboxymethyl cellulose, hydroxyethyl cellulose, substituted cellulose, polyacrylamide, polyethylene glycol, polyamides, polyureas, polyurethanes, polyester, polyethers, polystyrene, polysaccharide, polylactic acid, polyethylene, polymethylmethacrylate and copolymers or mixtures thereof.
  • a preferred polymer is polyvinyl alcohol.
  • the polyvinyl alcohol in particular, is hydrolyzed in the range of 80 to 99%.
  • the weight average molecular weight of the base polymer can be in the range of 9000 to 186,000, 85,000 to 146,000 or 89,000 to 98,000.
  • Gelling precursors include, for example, alginates, alginate salts, xanthan gums, natural gum, agar, agarose, chitosan, carrageenan, fucoidan, furcellaran, laminaran, hypnea, Vietnameseeuma, gum arabic, gum ghatti, gum karaya, gum tragacanth, hyaluronic acid, locust beam gum, arabinogalactan, pectin, amylopectin, other water soluble polysaccharides and other ionically crosslinkable polymers.
  • a particular gelling precursor is sodium alginate.
  • a preferred sodium alginate is high guluronic acid, stem-derived alginate (e.g.
  • PVA guluronic acid with a low viscosity e.g. about 20 to 80 cps at 20°C
  • High molecular weight PVA is dissolved in water by heating, typically above about 70°C, while alginates can be dissolved at room temperature.
  • the PVA can be dissolved by mixing PVA and alginate together in a vessel which is heated to autoclave temperature (about 121°C).
  • the PVA can be disposed in water and heated and the alginate subsequently added at room temperature to avoid exposing the alginate to high temperature. Heat can also be applied by microwave application.
  • the mixture is typically about 7.5 to 8.5%, e.g.
  • the viscosity controller 305 is a heat exchanger circulating water at a predetermined temperature about the flow tubing between the pump and drop generator.
  • the mixture of base polymer and gelling precursor flows into the viscosity controller 305, where the mixture is heated so that its viscosity is lowered to a level for efficient formation of very small drops.
  • the temperature of the circulating water is less than about 75°C and more than about 60°C, for example, 65°C which maintains the mixture at a viscosity of 90-200 centipoise.
  • the viscosity of the drops is maintained so they are captured in the gelling vessel without splintering or cojoining which can create irregular, fiberous particles.
  • the flow controller and/or the drop generator can be placed in a temperature-controlled chamber, e.g. an oven, or a heat tape wrap, to maintain a desired viscosity.
  • the drop generator 310 generates substantially spherical drops of predetermined diameter by forcing a stream of the mixture of base polymer and gelling precursor through a nozzle which is subject to a periodic disturbance to break up the jet stream into drops.
  • the jet stream can be broken into drops by vibratory action generated for example, by an electrostatic or piezoelectric element.
  • the drop size is controlled by controlling the flow rate, viscosity, amplitude, and frequency at which the element is driven. Lower flow rates and higher frequencies produce smaller drops.
  • a suitable electrostatic drop generator is available from NISCO Engineering, model NISCO Encapsulation unit VAR D, Zurich, Switzerland. In embodiments, the frequency is in the range of about 0.1 to 0.8 kHz.
  • the flow rate through the droplet generator is in the range of about 1 to 12 mL per minute.
  • the drop generator can include charging the drops after formation such that mutual repulsion between drops prevents drop aggregation as drops travel from the generator to the gelling vessels. Charging may be achieved by, e.g. an electrostatic charging device such as a charged ring positioned downstream of the nozzle.
  • the gelling vessel 320 contains a gelling agent which interacts with the gelling precursor to stabilize drops by forming a stable gel.
  • Suitable gelling agents include, for example, a divalent cation such as alkali metal salt, alkaline earth metal salt or a transition metal salt that can ionically crosslink with the gelling agent.
  • An inorganic salt for example, a calcium, barium, zinc or magnesium salt can be used as a gelling agent.
  • a suitable gelling agent is calcium chloride.
  • the calcium cations have an affinity for carboxylic groups in the gelling precursor.
  • the cations complex with carboxylic groups in the gelling precursor resulting in encapsulation of the base polymer in a matrix of gelling precursor.
  • the gelling agent is in an amount selected in accordance with the desired properties of the particles.
  • a pore structure in the particle forms in the gelling stage.
  • the concentration of the gelling agent can control pore formation in the particle, thereby controlling the porosity gradient in the particle.
  • Adding non-gelling ions, for example, sodium ions, to the gelling solution can reduce the porosity gradient, resulting in a more uniform intermediate porosity throughout the particle.
  • the gelling agent is, for example, 0.01-10 weight percent, 1-5 weight percent or 2 weight percent in deionized water.
  • particles, including gelling agent and a pore structure can be used in composition 27.
  • the gelling solution is decanted from the solid drops and the stabilized drops are transferred to the reactor vessel 330.
  • the stabilized drops are reacted to produce precursor particles.
  • the reactor vessel includes an agent that chemically reacts with the base polymer, e.g. to cause crosslinking between polymer chains and/or within a polymer chain.
  • the agent diffuses into the stabilized drops from the surface of the particle in a gradient which, it is believed, provides more crosslinking near the surface of the stabilized drop compared to the body and center of the drop. Reaction is greatest at the surface of the drop, providing a stiff, abrasion resistant exterior.
  • the vessel 330 includes aldehydes, such as formaldehyde, glyoxal, benzaldehyde, aterephthalaldehyde, succinaldehyde and glutaraldehyde for the acetalization of polyvinyl alcohol.
  • the vessel 330 also includes an acid, for example, strong acids such as sulfuric acid, hydrochloric acid, nitric acid and weak acids such as acetic acid, formic acid and phosphoric acid.
  • the reaction is primarily a 1,3 acetalization:
  • This intra-chain acetalization reaction can be carried out with relatively low probability of inter-chain crosslinking as described in John G. Pritchard "Poly(Vinyl Alcohol) Basic Properties And Uses (Polymer Monograph, vol. 4) (see p. 93-97), Gordon and Breach, Science Publishers LTD., London, 1970, the entire contents of which is hereby incorporated by reference. Some OH groups along a polymer chain can remain unconverted since the reaction proceeds in a random fashion and there can be left over OH groups that do not react with adjacent groups.
  • Adjusting the amount of aldehyde and acid used, reaction time and reaction temperature can control the degree of acetalization.
  • the reaction time is e.g., 5 minutes to 1 hour, 10 to 40 minutes or 20 minutes.
  • the reaction temperature can be 25 °C to 150 °C or 75 °C to 130 °C or 65 °C.
  • the reactor vessel is placed in a water bath fitted with an orbital motion mixer. The crosslinked precursor particles are washed several times with deionized water to neutralize the particles and remove any residual acidic solution.
  • the precursor particles are transferred to the dissolution chamber 340 to remove the gelling precursor, e.g. by an ion exchange reaction.
  • sodium alginate is removed by ion exchange with a solution of sodium hexa-metaphosphate (EM Science).
  • the solution can include, for example, ethylenediaminetetraacetic acid (EDTA), citric acid, other acids and phosphates.
  • EDTA ethylenediaminetetraacetic acid
  • the concentration of the sodium hexa-metaphosphate can be, for example, 1-20 weight %, 1-10 weight % or 5 weight % in deionized water.
  • Residual gelling precursor for example, sodium alginate
  • Residual gelling precursor can be determined by assay for detection of uronic acids in, for example, alginates containing mannuronic and guluronic acid residues. Suitable assays include rinsing the particles with sodium tetraborate in sulfuric acid solution to extract alginate and combining the extract with metahydroxydiphenyl colormetric reagent and determining concentration by UV/VIS spectroscopy. Testing can be carried out by alginate suppliers such as FMC Biopolymer, Oslo, Norway.
  • Residual alginate can be present in the range of about 20-35% by weight prior to rinsing and in the range of about 0.01-0.5%) or 0.1- 0.3% or 0.18% in the particles after rinsing for 30 minutes in water at about 23°C.
  • the particles are filtered through filter 350 to remove residual debris. Particles of
  • 500 to 700 microns are filtered through a sieve of 710 microns and then a sieve of 300 microns.
  • Particles of 700 to 900 microns are filtered through a sieve of 1000 microns and then a sieve of 500 microns.
  • Particles of 900 to 1200 microns are filtered through a sieve of 1180 microns and then a sieve of 710 microns.
  • the filtered particles are sterilized by a low temperature technique such as e-beam irradiation, and packaged.
  • electron beam irradiation can be used to pharmaceutically sterilize the particles to reduce bioburden.
  • e-beam sterilization an electron beam is accelerated using magnetic and electric fields, and focused into a beam of energy. This resultant beam can be scanned by means of an electromagnet to produce a "curtain" of accelerated electrons.
  • the accelerated electron beam penetrates the collection of particles to confer upon them electrons which destroy bacteria and mold to sterilize and reduce the bioburden in the particles.
  • Electron beam sterilization can be performed by sterilization vendors, such as Titan Scan, Lima, Ohio. [0067] Additional information about the particles is described in commonly assigned
  • Particles are manufactured from an aqueous solution containing 8 weight % of polyvinyl alcohol, 99+% hydrolyzed, average M w 89,000-120,000 (ALDRICH) and 2 weight% of gelling precursor, sodium alginate, PRONOVA UPLVG, (FMC BioPolymer, Princeton, NJ) in deionized water and the mixture is heated to about 121 °C.
  • the solution has a viscosity of about 310 centipoise at room temperature and a viscosity of about 160 cps at 65°C.
  • a syringe pump Hard Vard Apparatus
  • the mixture is fed to drop generator (Nisco Engineering).
  • Drops are directed into a gelling vessel containing 2 weight % of calcium chloride in deionized water and stirred with a stirring bar.
  • the calcium chloride solution is decanted within about three minutes to avoid substantial leaching of the polyvinyl alcohol from the drops into the solution.
  • the drops are added to the reaction vessel containing a solution of 4% by weight of formaldehyde (37 wt% in methanol) and 20% by weight sulfuric acid (95-98% concentrated).
  • the reaction solution is stirred at 65°C for 20 minutes.
  • Precursor particles are rinsed with deionized water (3 X 300 mL) to remove residual acidic solution.
  • the sodium alginate is substantially removed by soaking the precursor particles in a solution of 5 weight % of sodium hexa-methaphosphate in deionized water for 0.5 hour. The solution is rinsed in deionized water to remove residual phosphate and alginate. The particles are filtered by sieving, as discussed above, placed in saline (USP 0.9% NaCl) and followed by irradiation sterilization.
  • saline USP 0.9% NaCl
  • Suspendability is measured at room temperature by mixing a solution of 2 ml of particles in 5 ml saline with contrast solution (Omnipaque 300, Nycomed, Buckinghamshire, UK) and observing the time for about 50% of the particles to enter suspension, i.e. have not sunk to the bottom or floated to the top of a container (about 10 ml, 25 mm diameter vial). Suspendability provides a practical measure of how long the particles will remain suspended.
  • contrast solution Omnipaque 300, Nycomed, Buckinghamshire, UK
  • Omnipaque is an aqueous solution of lohexol, N.N.-Bis (2,3-dihydroxypropyl)-T-[N-(2,3- dihydroxypropyl)-acetamide]-2,4,6-trilodo-isophthalamide; Omnipaque 300 contains 647 mg of iohexol equivalent to 300 mg of organic iodine per ml. The specific gravity of 1.349 of 37 °C and an absolute viscosity 11.8 cp at 20 °C.) The particles remain in suspension for about 2 to 3 minutes.
  • RapidVUE Image Analyzer version 2.06 (Beckman Coulter, Miami, FL). Briefly, the RapidVUE takes an image of continuous-tone (gray-scale) form and converts it to a digital form through the process of sampling and quantization. The system software identifies and measures particles in an image in the form of a fiber, rod or sphere. Sphericity computation and other statistical definitions are in Appendix A, attached, which is a page from the RapidVUE operating manual.
  • particle size uniformity is illustrated for particles 700 - 900 micron.
  • the x-axis is the particle diameter.
  • the y-axis is the volume normalized percentage of particles at each particle size. The total volume of particles detected is computed and the volume of the particles at each diameter is divided by the total volume. The particles have distribution of particle sizes with variance of less than about + 15%.
  • non-spherical particles can be manufactured and formed by controlling, e.g., drop formation conditions or by postprocessing the particles, e.g. by cutting or dicing into other shapes. Particles can also be shaped by physical deformation followed by crosslinking. Particle shaping is described in U.S. Serial No. 10/116,330, filed April 4, 2002.
  • Composition 27 can include one or more carrier materials that allow the composition to be delivered in a first state, e.g., a relatively fluid or low viscosity state, and change, e.g., by phase transition, to a second state, e.g., a relatively high viscosity or rigid state.
  • particles 25 can be suspended in a biocompatible, resorbable lubricant, such as a cellulose polysaccharide gel having water, glycerin and sodium carboxymethylcellulose. The gel enables particles 25 to remain in suspension without settling.
  • Other polysaccharides can also be included such as cellulose, agar methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, microcrystalline cellulose, oxidized cellulose, and other equivalent materials.
  • the polysaccharide gel is biocompatible, and the lubricious nature of the polysaccharide gel can reduce the frictional forces generated during the transferring of the particles from a syringe by injection into the tissue site.
  • polysaccharides do not generate an antigenic response, and the polysaccharide gel is readily sterilizable and stable at ambient conditions and does not need refrigeration for storage and shipment.
  • composition 27 After injection of composition 27 into the tissue, the polysaccharide gel can be resorbed by the tissue, leaving the non-resorbable matrix of particles 25 in place in the particular area or bolus, where it can remain without migrating to other areas of the body.
  • carriers include undiluted agarose, methyl cellulose or other linear unbranched polysaccharide, dextran sulfate, succinylated non-crosslinked collagen, methylated non-crosslinked collagen, glycogen, dextrose, maltose, triglycerides of fatty acids, egg yolk phospholipids, heparin, DMSO, phosphate buffered saline, and the like.
  • Examples of collagen are described in U.S. 5,490,984.
  • appropriate carriers include hyaluronic acid, polyvinyl pyrrolidone or a hydrogel derived thereof, dextran or a hydrogel derivative thereof, glycerol, polyethylene glycol, succinylated collagen, liquid collagen, oil based emulsions such as corn oil or safflower, B-D glucose (or B-glucan, as described in U.S. 6,277,392) or other polysachaarides or biocompatible organic polymers either singly or in combination with one or more of the above materials.
  • Hydrogel compositions such as those that swell upon injection into tissue due to hydration by physicologic fluid, are described, for example, in U.S. 6,423,332; U.S. 6,306,418; and 5,902,832.
  • the composition can swell from an initial dehydrated volume to a final hydrated volume that is substantially the same as the initial total volume of composition injected into the tissue to be treated.
  • Examples include poly(ethylene oxide), polyvinyl pyrrolidone, polyvinyl alcohol, poly(propylene oxide), poly(ethylene, glycol), poly(propylene glycol), polytetramethylene oxide, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxy ethyl methacrylate), hydroxy ethyl cellulose, hydroxy propyl cellulose, methoxylated pectin gels, agar, a starch such as cornstarch, a modified starch, an alginate, a hydroxy ethyl carbohydrate, or the like and should preferably be adjusted so as to allow swelling to a selected percent after hydration.
  • the carrier can disperse over time.
  • composition 27 includes between about 0.5 to about 50 weight percent of the carrier.
  • composition 27 can include greater than or equal to about 0.5, 5, 10, 15, 20, 25, 30, 35, 40, or 45 weight percent of the carrier; and/or less than or equal to about 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 weight percent of the carrier.
  • composition 27 includes a contrasting agent.
  • the contrast agent can be a biocompatible material capable of being monitored during injection by, for example, radiography, fluoroscopy, ultrasound, or visually.
  • the contrast agent can be water soluble or water insoluble.
  • water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
  • water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is available in a form for in vivo use including a particle size of about 10 microns or less.
  • Other water insoluble contrast agents include gold, tungsten, and platinum powders.
  • radiopaque materials include paramagnetic materials (e.g. persistent free radicals) and compounds, salts, and complexes of paramagnetic metal species (e.g., transition metal or lanthanide ions); heavy atom (e.g., atomic number of 37 or more) compounds, salts, or complexes (e.g., heavy metal compounds, iodinated compounds, etc.); radionuclide-containing compounds, salts, or complexes (e.g. salts, compounds or complexes of radioactive metal isotopes or radiodinated organic compounds); and superparamagentic materials (e.g., metal oxide or mixed oxide particles, particularly iron oxides).
  • paramagnetic materials e.g. persistent free radicals
  • compounds, salts, and complexes of paramagnetic metal species e.g., transition metal or lanthanide ions
  • heavy atom e.g., atomic number of 37 or more
  • Paramagnetic metals include Gd (III), Dy (III), Fe (II), Fe (III), Mn (III) and Ho (III), and paramagnetic Ni, Co and Eu species.
  • Heavy metals include Pb, Ba, Ag, Au, W, Cu, Bi and lanthanides such as Gd.
  • Metals, metal oxides, and alloys including but not limited to medical grade stainless steel, silver, gold, titanium and titanium alloys, oxide derivatives of stainless steel or titanium or titanium alloys, aluminum oxide, and zirconium oxide can also be used.
  • the amount of contrasting agent used can be any amount sufficient to be detected.
  • particles 25 include one or more therapeutic agents.
  • an effective amount of wound healing agents can be added to composition 27.
  • These agents include protein growth factors such as fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), epidermal growth factors (EGFs), connective tissue activated peptides (CTAPs), transforming growth factors (TGFs), and the like.
  • FGFs fibroblast growth factors
  • PDGFs platelet derived growth factors
  • EGFs epidermal growth factors
  • CTAPs connective tissue activated peptides
  • TGFs transforming growth factors
  • composition 27 includes antimicrobial additives and or antibodies to reduce the potential for infection at the treatment site.
  • Other agents are described in commonly assigned U.S.S.N. [Attorney Docket No. 01194-438001], filed on August 30,
  • the therapeutic agent can be added to composition 27 and/or be placed on particles 25.
  • Composition 27 can include one or more materials that enhance the mechanical and/or physical properties of the composition.
  • particles 25 can be combined with one or more relatively hard materials.
  • the relatively hard material can be, for example, biocompatible ceramics, biocompatible metals (e.g., stainless steel), glass, or other biocompatible materials such as calcium salts, e.g., hydroxyapatite.
  • the combination of particles 25 and hard material(s) can be used, for example, to fill depressed scars, unsymmetrical orbital floors, or bone defects in reconstructive surgical procedures.
  • particles 25 and/or composition 27 can be placed laproscopically. Particles 25 and/or composition 27 can also be placed in a cavity or void created in tissue.
  • a method of placing particles 25 and/or composition 27 includes using a catheter or a sheath 402, e.g., a blunt-ended hypotube, configured to proximally receive a penetration device 404, e.g., one having a trocar at its distal end.
  • Penetration device 404 is inserted into sheath 402 to allow the sheath to penetrate into tissue 403 (Fig. 7A).
  • the penetration depth can be determined by striping 406 formed on sheath 402.
  • the tip of penetration device 404 can penetrate about 2-2.5 cm into tissue 403, while the tip of sheath 402 can penetrate about 0.5- 1 cm into the tissue.
  • penetration device 404 is withdrawn from sheath 402, which is retained penetrated in the tissue (Fig. 7B).
  • a catheter 406 carrying an uninflated balloon 408 at the distal end is then inserted into sheath 402 (Fig. 7C) such that the balloon extends into tissue 403.
  • Balloon 408 is then inflated using an inflation device, such as a syringe 410 containing saline (Fig. 7D). As balloon 408 inflates, it creates a cavity or a void 412 in tissue 403. In embodiments, balloon 408 is shaped to provide a cavity with a predetermined shape. Balloon 408 is then deflated, and catheter 406 is withdrawn from sheath 402 (Fig. 7E).
  • An injection device 414 such as a syringe 416 containing particles 25 and/or composition 27, is then inserted into sheath 402, and the particles and or composition can be delivered to cavity 412 (Fig. 7F).
  • particles 25 and/or composition 27 can be used with a device, such as an indwelling sling, used to treat urinary incontinence.
  • a device such as an indwelling sling
  • An example of a device is described in WO 00/74633.
  • Particles 25 and/or composition 27 can be placed, e.g., injected, into the device as a bulking agent to provide lift, thereby providing another method of adjusting the degree of support provided by the device.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de traitement de tissu consistant à placer des particules polymères sensiblement sphériques dans le tissu. Les particules comprennent une région intérieure possédant des pores relativement grands et une première région entourant sensiblement l'intérieur et possédant un nombre inférieur de pores relativement grands par rapport à la région intérieure.
PCT/US2003/009467 2002-03-29 2003-03-28 Traitement de tissu WO2003082359A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002480630A CA2480630A1 (fr) 2002-03-29 2003-03-28 Traitement de tissu
EP03719492A EP1490119A1 (fr) 2002-03-29 2003-03-28 Traitement de tissu
AU2003223372A AU2003223372A1 (en) 2002-03-29 2003-03-28 Tissue treatment
JP2003579891A JP4364649B2 (ja) 2002-03-29 2003-03-28 組織処置物質として使用されるポリマー粒子

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/109,966 US7094369B2 (en) 2002-03-29 2002-03-29 Processes for manufacturing polymeric microspheres
US10/109,966 2002-03-29
US11633002A 2002-04-04 2002-04-04
US10/116,330 2002-04-04
US10/231,664 US7131997B2 (en) 2002-03-29 2002-08-30 Tissue treatment
US10/231,664 2002-08-30

Publications (1)

Publication Number Publication Date
WO2003082359A1 true WO2003082359A1 (fr) 2003-10-09

Family

ID=28678826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009467 WO2003082359A1 (fr) 2002-03-29 2003-03-28 Traitement de tissu

Country Status (5)

Country Link
EP (1) EP1490119A1 (fr)
JP (1) JP4364649B2 (fr)
AU (1) AU2003223372A1 (fr)
CA (1) CA2480630A1 (fr)
WO (1) WO2003082359A1 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020011A1 (fr) * 2002-08-30 2004-03-11 Boston Scientific Limited Embolisation
US6773441B1 (en) 1999-06-22 2004-08-10 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
DE102004019241A1 (de) * 2004-04-16 2005-11-03 Cellmed Ag Injizierbare vernetzte und unvernetzte Alginate und ihre Verwendung in der Medizin und in der ästhetischen Chirurgie
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
JP2007510650A (ja) * 2003-11-04 2007-04-26 ボストン サイエンティフィック リミテッド ポリマー粒子および放射線不透過性材料からなる塞栓組成物
JP2007513083A (ja) * 2003-11-10 2007-05-24 アンジオテック インターナショナル アーゲー 医療用移植片および繊維誘発剤
JP2007533393A (ja) * 2004-04-23 2007-11-22 アドリアーン アルバータス コツェ，ヤコブス セラミック充填剤
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
WO2009032430A2 (fr) 2007-08-31 2009-03-12 Zimmer Inc. Hydrogels avec gradient
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7947369B2 (en) 2005-05-26 2011-05-24 Daicel-Degussa Ltd. Production of fine spherical thermoplastic resin particles
EP1511522B1 (fr) * 2002-06-12 2011-08-10 Boston Scientific Limited Agents gonflants
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
US9198568B2 (en) 2010-03-04 2015-12-01 The General Hospital Corporation Methods and systems of matching voice deficits with a tunable mucosal implant to restore and enhance individualized human sound and voice production
US9216188B2 (en) 2008-09-04 2015-12-22 The General Hospital Corporation Hydrogels for vocal cord and soft tissue augmentation and repair
US9283035B2 (en) 2005-04-28 2016-03-15 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
CN106729953A (zh) * 2016-12-29 2017-05-31 苏州恒瑞迦俐生生物医药科技有限公司 一种功能化改性聚乙烯醇栓塞微球及其制备方法
CN107899066A (zh) * 2017-12-01 2018-04-13 苏州恒瑞迦俐生生物医药科技有限公司 阳离子多羟基聚合物栓塞微球及其制备方法
US10555801B2 (en) 2018-03-05 2020-02-11 Olympus Corporation Gastrointestinal-tract constricting method
US10561489B2 (en) 2018-03-05 2020-02-18 Olympus Corporation Gastrointestinal-tract constricting method
US10857020B2 (en) 2017-09-14 2020-12-08 Olympus Corporation Gastrointestinal track constricting method
US10918454B2 (en) 2018-04-02 2021-02-16 Olympus Corporation Gastrointestinal tract constricting method
US12239557B2 (en) 2018-04-06 2025-03-04 Olympus Corporation Drug supply device

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0701811L (sv) * 2007-08-02 2008-08-26 Novoaim Ab Kirurgiskt kit för fettransplantation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402031A2 (fr) * 1989-06-09 1990-12-12 American Medical Systems, Inc. Corps polymériques injectables
WO1993019702A1 (fr) * 1992-04-06 1993-10-14 Uroplasty, Inc. Traitement de troubles dus a des reflux par injection de microparticules
EP0730847A1 (fr) * 1995-03-07 1996-09-11 Menlo Care Inc. Matériau pour augmenter la fonction du sphincter à expansion contrÔlée
WO2001070291A2 (fr) * 2000-03-20 2001-09-27 Biosphere Medical, Inc. Microspheres injectables destinees a l'augmentation dermique et au gonflement tissulaire
US6315709B1 (en) * 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US20010051670A1 (en) * 2000-03-13 2001-12-13 Goupil Dennis W. Tissue bulking and coating compositions
JP2002017848A (ja) * 2000-07-12 2002-01-22 Terumo Corp 生体内注入可能な微粒子およびその製造法
WO2002011696A2 (fr) * 2000-08-08 2002-02-14 Ev & M Matieres et procede pour l'augmentation active de tissus
DE10026620A1 (de) * 2000-05-29 2002-03-07 Gerhard Quelle Poröse Implantate und Partikel

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402031A2 (fr) * 1989-06-09 1990-12-12 American Medical Systems, Inc. Corps polymériques injectables
WO1993019702A1 (fr) * 1992-04-06 1993-10-14 Uroplasty, Inc. Traitement de troubles dus a des reflux par injection de microparticules
EP0730847A1 (fr) * 1995-03-07 1996-09-11 Menlo Care Inc. Matériau pour augmenter la fonction du sphincter à expansion contrÔlée
US6315709B1 (en) * 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US20010051670A1 (en) * 2000-03-13 2001-12-13 Goupil Dennis W. Tissue bulking and coating compositions
WO2001070291A2 (fr) * 2000-03-20 2001-09-27 Biosphere Medical, Inc. Microspheres injectables destinees a l'augmentation dermique et au gonflement tissulaire
DE10026620A1 (de) * 2000-05-29 2002-03-07 Gerhard Quelle Poröse Implantate und Partikel
JP2002017848A (ja) * 2000-07-12 2002-01-22 Terumo Corp 生体内注入可能な微粒子およびその製造法
WO2002011696A2 (fr) * 2000-08-08 2002-02-14 Ev & M Matieres et procede pour l'augmentation active de tissus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200237, Derwent World Patents Index; Class A96, AN 2002-333654, XP002250417 *
YUSI G M ET AL: "Submucosal injection of polyvinyl alcohol in artificially created vesico-ureteral reflux: A preliminary report", ASIAN JOURNAL OF SURGERY 1995 HONG KONG, vol. 18, no. 2, 1995, pages 122 - 127, XP008020559, ISSN: 1015-9584 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773441B1 (en) 1999-06-22 2004-08-10 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US7736373B2 (en) 1999-06-22 2010-06-15 Ndo Surical, Inc. Methods and devices for tissue reconfiguration
US7896893B2 (en) 1999-06-22 2011-03-01 Ethicon Endo-Surgery, Inc. Methods and devices for tissue reconfiguration
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7611542B2 (en) 2002-03-29 2009-11-03 Boston Scientific Scimed, Inc. Tissue treatment
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7588780B2 (en) 2002-03-29 2009-09-15 Boston Scientific Scimed, Inc. Embolization
US7507772B2 (en) 2002-04-04 2009-03-24 Boston Scientific Scimed, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7288319B2 (en) 2002-04-04 2007-10-30 Boston Scientific Scimed Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
EP1511522B1 (fr) * 2002-06-12 2011-08-10 Boston Scientific Limited Agents gonflants
US10398724B2 (en) 2002-06-12 2019-09-03 Boston Scientific Scimed, Inc. Bulking agents
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
WO2004020011A1 (fr) * 2002-08-30 2004-03-11 Boston Scientific Limited Embolisation
US9931429B2 (en) * 2002-08-30 2018-04-03 Boston Scientific Scimed, Inc. Embolization
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US8273324B2 (en) 2002-08-30 2012-09-25 Boston Scientific Scimed, Inc. Embolization
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
JP2007510650A (ja) * 2003-11-04 2007-04-26 ボストン サイエンティフィック リミテッド ポリマー粒子および放射線不透過性材料からなる塞栓組成物
JP2007513083A (ja) * 2003-11-10 2007-05-24 アンジオテック インターナショナル アーゲー 医療用移植片および繊維誘発剤
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
DE102004019241A1 (de) * 2004-04-16 2005-11-03 Cellmed Ag Injizierbare vernetzte und unvernetzte Alginate und ihre Verwendung in der Medizin und in der ästhetischen Chirurgie
US8163714B2 (en) 2004-04-16 2012-04-24 Cellmed Ag Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery
JP2007533393A (ja) * 2004-04-23 2007-11-22 アドリアーン アルバータス コツェ，ヤコブス セラミック充填剤
US7666333B2 (en) 2004-06-01 2010-02-23 Boston Scientific Scimed, Inc. Embolization
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US9283035B2 (en) 2005-04-28 2016-03-15 Boston Scientific Scimed, Inc. Tissue-treatment methods
US7947369B2 (en) 2005-05-26 2011-05-24 Daicel-Degussa Ltd. Production of fine spherical thermoplastic resin particles
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
WO2009032430A2 (fr) 2007-08-31 2009-03-12 Zimmer Inc. Hydrogels avec gradient
WO2009032430A3 (fr) * 2007-08-31 2009-05-28 Zimmer Inc Hydrogels avec gradient
US9216188B2 (en) 2008-09-04 2015-12-22 The General Hospital Corporation Hydrogels for vocal cord and soft tissue augmentation and repair
US9682169B2 (en) 2008-09-04 2017-06-20 Massachusetts Institute Of Technology Hydrogels for vocal cord and soft tissue augmentation and repair
US9198568B2 (en) 2010-03-04 2015-12-01 The General Hospital Corporation Methods and systems of matching voice deficits with a tunable mucosal implant to restore and enhance individualized human sound and voice production
CN106729953A (zh) * 2016-12-29 2017-05-31 苏州恒瑞迦俐生生物医药科技有限公司 一种功能化改性聚乙烯醇栓塞微球及其制备方法
US10857020B2 (en) 2017-09-14 2020-12-08 Olympus Corporation Gastrointestinal track constricting method
CN107899066A (zh) * 2017-12-01 2018-04-13 苏州恒瑞迦俐生生物医药科技有限公司 阳离子多羟基聚合物栓塞微球及其制备方法
CN107899066B (zh) * 2017-12-01 2021-02-09 苏州恒瑞迦俐生生物医药科技有限公司 阳离子多羟基聚合物栓塞微球及其制备方法
US10555801B2 (en) 2018-03-05 2020-02-11 Olympus Corporation Gastrointestinal-tract constricting method
US10561489B2 (en) 2018-03-05 2020-02-18 Olympus Corporation Gastrointestinal-tract constricting method
US10918454B2 (en) 2018-04-02 2021-02-16 Olympus Corporation Gastrointestinal tract constricting method
US12239557B2 (en) 2018-04-06 2025-03-04 Olympus Corporation Drug supply device

Also Published As

Publication number Publication date
EP1490119A1 (fr) 2004-12-29
AU2003223372A1 (en) 2003-10-13
CA2480630A1 (fr) 2003-10-09
JP4364649B2 (ja) 2009-11-18
JP2005521476A (ja) 2005-07-21

Similar Documents

Publication Publication Date Title
US7611542B2 (en) Tissue treatment
JP4364649B2 (ja) 組織処置物質として使用されるポリマー粒子
US7449236B2 (en) Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7842377B2 (en) Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7666333B2 (en) Embolization
US7588780B2 (en) Embolization
AU2003259723B2 (en) Embolization
JP5025873B2 (ja) 組織増量及び被覆用組成物
US8318195B2 (en) Controlling resorption of bioresorbable medical implant material by application of microwave, ultrasound or radiofrequencies
JP2005537070A (ja) 塞栓術
AU2002306707A1 (en) Controlled resorption of medical implants
EP1490120B1 (fr) Embolisation
JP4809581B2 (ja) 塞栓組成物及び塞栓粒子の製造方法
AU2007234593B2 (en) Controlled resorption of medical implants
JP2024509627A (ja) 尿または便失禁の処置における使用のための組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003719492

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003223372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2480630

Country of ref document: CA

Ref document number: 2003579891

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003719492

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载